| Yannan Zhao,Biyun Wang. Systemic chemotherapy for metastatic breast cancer. Oncol Transl Med, 2015, 1: 226-232. |
| Systemic chemotherapy for metastatic breast cancer |
| Received:December 29, 2014 Revised:September 29, 2015 |
| View Full Text View/Add Comment Download reader |
| KeyWord:chemotherapy; metastatic breast cancer (MBC); single-agent chemotherapy; combination chemotherapy; triple-negative breast cancer; maintenance treatment |
| Author Name | Affiliation | E-mail | | Yannan Zhao | Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,200032,China | 14211230018@fudan.edu.cn | | Biyun Wang | Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,200032,China | wangbiyun0107@hotmail.com |
|
| Hits: 6476 |
| Download times: 8031 |
| Abstract: |
| Breast cancer is the leading cause of cancer among women worldwide and the most common cancer in China. Many factors influence the treatment strategy for metastatic breast cancer (MBC). Chemotherapy should be administered to patients with hormone receptor-negative tumors, symptomatic visceral metastasis, and a short disease-free interval. Sequential single-agent chemotherapy has similar efficacy as combination agents in terms of overall survival and quality of life. Anthracyclines are the cornerstone of first-line treatment for MBC, and taxanes represent the second treatment option after resistance. When progression or intolerable toxicity occurs after optimal treatment, the alternative treatments include capecitabine, vinorelbine, and gemcitabine. Ixabepilone and eribulin are relatively new effective single agents. A combination of cytotoxic agents for patients with rapid clinical progression can further improve the overall response rate and time to progression compared to single-agent treatment. For patients with MBC who were pretreated with anthracyclines in the eoadjuvant/adjuvant setting, a taxane-containing regimen such as docetaxel plus capecitabine or gemcitabine plus paclitaxel should be administered. Platinum-based therapies such as cisplatin or carboplatin have a role in the treatment of triple-negative breast cancer. Meanwhile, the efficacy of the addition of targeted drugs such as iniparib, bevacizumab, and cetuximab to chemotherapy remains unproven. Maintenance chemotherapy is routinely recommended in clinical practice at present. Patients who were previously treated with paclitaxel and gemcitabine have better progression-free and overall survival with maintenance chemotherapy according to a Korean phase III clinical trial. Sequential maintenance treatment with capecitabine monotherapy after capecitabine-based combination chemotherapy (X-based X) appears favorable based on a series of domestic studies. |
| Close |
|
|
|